Aspira Women's Health Receives Final Crosswalk Pricing Determination From CMS; CMS Approves OvaWatchSM 2024 Price At $897 Per Test
Portfolio Pulse from Bill Haddad
Aspira Women's Health has received the final crosswalk pricing determination from the Centers for Medicare & Medicaid Services (CMS). CMS has set the 2024 price for Aspira's OvaWatchSM test at $897 per test.
November 27, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aspira Women's Health's OvaWatchSM test has been priced at $897 by CMS for 2024, which could influence the company's revenue and market positioning in women's health diagnostics.
The CMS pricing determination is a critical regulatory decision that directly affects Aspira Women's Health's revenue potential for the OvaWatchSM test. The approved price of $897 per test for 2024 is likely to be factored into the company's financial projections and could positively impact investor sentiment in the short term. Given that this is a final determination, the confidence in the impact of this news on AWH's stock is high.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100